C. Wikstrand

发表

EGFRvIII as a promising target for antibody-based brain tumor therapy

D. Bigner, C. Kuan, C. Wikstrand, 2006, Brain Tumor Pathology.

EGF mutant receptor vIII as a molecular target in cancer therapy.

D. Bigner, D D Bigner, C. Kuan, 2001, Endocrine-related cancer.

Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors.

A. Friedman, D. Bigner, G. Dranoff, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene.

P. Humphrey, D. Bigner, S. Batra, 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Heterogeneity of Genotypic and Phenotypic Characteristics of Fifteen Permanent Cell Lines Derived from Human Gliomas

D. Bigner, S. Bigner, E. Ruoslahti, 1981, Journal of neuropathology and experimental neurology.

Development of a syngeneic rat brain tumor model expressing EGFRvIII and its use for molecular targeting studies with monoclonal antibody L8A4.

B. Ross, B. Moffat, M. Ciesielski, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Resistance to Tyrosine Kinase Inhibition by Mutant Epidermal Growth Factor Receptor Variant III Contributes to the Neoplastic Phenotype of Glioblastoma Multiforme

A. Friedman, D. Bigner, H. Friedman, 2004, Clinical Cancer Research.

C. Kuan, C. Wikstrand, D. Bigner, 2001 .

Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII).

D. Bigner, S. Batra, H. Kung, 1997, The Biochemical journal.

EGF-R, and de2 Δ Receptor (EGF-RvIII, to Mutated Epidermal Growth Factor Immune Responses of Breast Cancer Patients

F. Marincola, D. Bigner, A. Klein-Szanto, 2013 .

Immune Responses of Breast Cancer Patients to Mutated Epidermal Growth Factor Receptor (EGF-RvIII, ΔEGF-R, and de2–7 EGF-R)1

F. Marincola, D. Bigner, A. Klein-Szanto, 2004, The Journal of Immunology.

EGF-R ) 7 − EGFR , and de 2 ∆ Receptor ( EGF-RvIII , to Mutated Epidermal Growth Factor Immune Responses of Breast Cancer Patients and Dorothee Herlyn

F. Marincola, D. Bigner, A. Klein-Szanto, 2004 .

Monoclonal antibodies for brain tumour treatment

D. Bigner, D. Reardon, M. Zalutsky, 2004, Expert opinion on biological therapy.

Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII‐specific scFv

I. Pastan, D. Bigner, M. Zalutsky, 2000, International journal of cancer.

Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.

R. Coleman, R. McLendon, A. Friedman, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.

R. Coleman, R. McLendon, A. Friedman, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic applications of the epidermal growth factor receptor and its ligand, transforming growth factor-alpha.

D. Bigner, C. Wikstrand, 1998, Journal of the National Cancer Institute.

Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.

R. McLendon, S. Keir, D. Bigner, 2005, Molecular cancer therapeutics.

Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors.

A. Friedman, K. Hess, D. Bigner, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Glioma-associated Antigen Expression in Oligodendroglial Neoplasms: Tenascin and Epidermal Growth Factor Receptor

R. McLendon, D. Bigner, S. Bigner, 2000, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Monoclonal Antibodies against EGFRvIII Are Tumor Specific and React with Breast and Lung Carcinomas and Malignant ( Â ¿ liornas 1

R. McLendon, P. Humphrey, D. Bigner, 2006 .

Molecular TargetingandTreatmentof Composite EGFRand EGFRvIII-Positive Gliomas Using BoronatedMonoclonal Antibodies

K. Tordoff, M. Ciesielski, R. Fenstermaker, 2008 .

MolecularTargeting and Treatment of EGFRvIII-Positive Gliomas Using BoronatedMonoclonal Antibody L 8 A 4

M. Moeschberger, A. Ferketich, M. Ciesielski, 2006 .

Anti-GM2 monoclonal antibodies induce necrosis in GM2-rich cultures of a human glioma cell line.

D. Bigner, R. Bjerkvig, O. Engebraaten, 1991, Cancer research.

Convection enhanced delivery of boronated EGF as a molecular targeting agent for neutron capture therapy of brain tumors

B. Ross, M. Ciesielski, R. Fenstermaker, 2009, Journal of Neuro-Oncology.

Comparison of monoclonal antibody delivery to intracranial glioma xenografts by intravenous and intracarotid administration.

D. Bigner, L. Muhlbaier, M. Zalutsky, 1987, Cancer research.

Tenascin expression in human glioma cell lines and normal tissues

D. Bigner, L. Ostrowski, C. Wikstrand, 1992, Journal of Neuroimmunology.

Phase I studies of treatment of malignant gliomas and neoplastic meningitis with131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab′)2-a preliminary report

R. Coleman, R. McLendon, A. Friedman, 2005, Journal of Neuro-Oncology.

Therapeutic efficacy of antiglioma mesenchymal extracellular matrix 131I-radiolabeled murine monoclonal antibody in a human glioma xenograft model.

R. Coleman, D. Bigner, H. Friedman, 1988, Cancer Research.

Glycoprotein Nonmetastatic Melanoma Protein B, a Potential Molecular Therapeutic Target in Patients with Glioblastoma Multiforme

G. Riggins, D. Bigner, J. Herndon, 2006, Clinical Cancer Research.

Brain Tumor Working Group Report on the 9th International Conference on Brain Tumor Research and Therapy

Charles B. Wilson, M. Israel, J. Fike, 1993, Journal of Neuro-Oncology.

Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein tenascin

S. Morrison, D. Bigner, S. Batra, 1994, Journal of Neuroimmunology.

Production and Characterization of Two Human Glioma Xenograft-localizing Monoclonal Antibodies1

R. McLendon, D. Bigner, L. Svennerholm, 2006 .

Production and Characterization of Two Human Glioma Xenograft-localizing Monoclonal Antibodies 1

R. McLendon, D. Bigner, L. Svennerholm, 2006 .

Demonstration of complex antigenic heterogeneity in a human glioma cell line and eight derived clones by specific monoclonal antibodies.

D. Bigner, S. Bigner, C. Wikstrand, 1983, Cancer research.

Poliovirus receptor CD155-targeted oncolysis of glioma.

D. Bigner, J. Sampson, M. Gromeier, 2004, Neuro-oncology.

Long term response in a patient with neoplastic meningitis secondary to melanoma treated with 131I‐radiolabeled antichondroitin proteoglycan sulfate Mel‐14 F(ab′)2

D. Bigner, J. Provenzale, H. Friedman, 2001, Cancer.

Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects.

R. McLendon, A. Friedman, D. Bigner, 2007, Nuclear medicine and biology.

Induction of lethal experimental allergic encephalomyelitis in nonhuman primates and guinea pigs with human glioblastoma multiforme tissue.

D. Bigner, C. Wikstrand, O. M. Pitts, 1981, Journal of neurosurgery.

Five new epitope-defined monoclonal antibodies reactive with GM2 and human glioma and medulloblastoma cell lines.

D. Bigner, J. Månsson, L. Svennerholm, 1989, Cancer research.

Occurrence of Lacto Series Gangliosides 3'-isoLM1 and 3',6'-isoLD1 in Human Gliomas in vitro and in vivo

D. Bigner, G. Fuller, S. Bigner, 1991, Journal of neuropathology and experimental neurology.

Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results.

R. Coleman, R. McLendon, A. Friedman, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Immunobiologic aspects of the brain and human gliomas. A review.

D. Bigner, C. Wikstrand, 1980, The American journal of pathology.

Medulloblastoma cell-substrate interaction in vitro.

D. Bigner, H. Friedman, C. Wikstrand, 1991, Invasion & metastasis.

Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors.

I. Pastan, S. Batra, C. Wikstrand, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

AN INVESTIGATION OF ALLOGRAFT TOLERANCE: DISCORDANT REACTIVITY TO MURINE H‐Y-INCOMPATIBLE LYMPHOID CELL (PEC) AND SKIN GRAFTS

C. Wikstrand, G. Haughton, J. Daly, 1979, Transplantation.

Glycoprotein Nonmetastatic Melanoma Protein B, a Potential Molecular Therapeutic Target in Patients with Glioblastoma Multiforme

G. Riggins, D. Bigner, J. Herndon, 2006, Clinical Cancer Research.

Expression of human fetal brain antigens by human tumors of neuroectodermal origin as defined by monoclonal antibodies.

D. Bigner, C. Wikstrand, 1982, Cancer research.

Phenotypic and genotypic analysis of a human medulloblastoma cell line and transplantable xenograft (D341 Med) demonstrating amplification of c-myc.

J. Trojanowski, P. Burger, S. Bigner, 1988, The American journal of pathology.

Variant of the Epidermal Growth Factor Receptor , EGFRvIII Cell Surface Localization and Density of the Tumor-associated Updated

R. McLendon, A. Friedman, D. Bigner, 2006 .

A MONOCLONAL ANTIBODY RECOGNIZING HUMAN THY‐ 1: DISTRIBUTION ON HUMAN AND NON‐HUMAN PRIMATE HAEMATOPOIETIC CELLS

K. Foon, R. Schroff, R. Seeger, 1984, Journal of immunogenetics.

Establishment and Characterization of the Human Medulloblastoma Cell Line and Transplantable Xenograft D283 Med

J. Trojanowski, D. Bigner, P. Burger, 1985, Journal of neuropathology and experimental neurology.

Comparative localization of glioma-reactive monoclonal antibodies in vivo in an athymic mouse human glioma xenograft model

R. McLendon, D. Bigner, N. Tribolet, 1987, Journal of Neuroimmunology.

Ganglioside mapping of a human medulloblastoma xenograft

D. Bigner, H. Friedman, J. Gottfries, 2004, Acta Neuropathologica.

Lactotetraose series ganglioside 3',6'-isoLD1 in tumors of central nervous and other systems in vitro and in vivo.

R. McLendon, D. Bigner, G. Fuller, 1993, Cancer research.

Glycolipids and glycosyltransferases in permanent cell lines established from human medulloblastomas.

D. Bigner, H. Friedman, J. Gottfries, 1991, Biochimica et biophysica acta.

Determination of Gangliosides in Six Human Primary Medulloblastomas

V. P. Collins, D. Bigner, J. Gottfries, 1990, Journal of neurochemistry.

Characterization of the binding epitope of the monoclonal antibody DMAb-1 to ganglioside GM2.

D. Bigner, J. Månsson, L. Svennerholm, 1990, Biochimica et biophysica acta.

Detection of amino-terminal extracellular domain of somatostatin receptor 2 by specific monoclonal antibodies and quantification of receptor density in medulloblastoma.

R. McLendon, D. Bigner, M. Zalutsky, 2009, Hybridoma.

Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII.

R. McLendon, A. Friedman, D. Bigner, 1997, Cancer research.

Characterization of three restricted specificity monoclonal antibodies raised against the human glioma cell line D-54 MG

D. Bigner, S. Bigner, C. Wikstrand, 1984, Journal of Neuroimmunology.

The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target.

D. Bigner, M. Zalutsky, G. Archer, 1998, Journal of neurovirology.

Uptake in Tumor Xenografts Radioiodination Method Enhances Cellular Retention and III Monoclonal Antibodies : Use of the Tyramine-Cellobiose Tumor-specific Anti-Epidermal Growth Factor Receptor Variant

Ganesan, M. Willingham, R. Zalutsky, 2006 .

Poliovirus receptor CD155–targeted oncolysis of glioma 1

D. Bigner, J. Sampson, M. Gromeier, 2003 .

Use of Monoclonal Antibodies in Neurobiology and Neurooncology

D. Bigner, C. Wikstrand, 1985 .

Medulloblastoma: tumor biological and clinical perspectives

D. Bigner, S. Bigner, H. Friedman, 1991, Journal of Neuro-Oncology.

Immunobiology of malignant astrocytomas.

D. Bigner, S. Kurpad, C. Wikstrand, 1994, Seminars in oncology.

Glioma-associated antigens defined by monoclonal antibodies against an avian sarcoma virus-induced rat astrocytoma

D. Bigner, C. Wikstrand, Yi-sheng Lee, 1986, Journal of Neuroimmunology.

Monoclonal antibodies to malignant human gliomas.

P. Humphrey, D. Bigner, S. Bigner, 1992, Molecular and chemical neuropathology.

Human fetal brain antigen expression common to tumors of neuroectodermal tissue origin Gliomas, neuroblastomas, and melanomas

D. Bigner, C. Wikstrand, M. Bourdon, 1982, Journal of Neuroimmunology.

Epidermal Growth Factor Receptor VIII Peptide Vaccination Is Efficacious against Established Intracerebral Tumors 1

A. Friedman, K. Hess, D. Bigner, 2003 .

The Applications of Monoclonal Antibodies in Neuro-Oncology

R. McLendon, D. Bigner, P. Humphrey, 1987 .

Surface antigens of human glioma cells shared with normal adult and fetal brain.

D. Bigner, C. Wikstrand, 1979, Cancer research.

Immunobiology of primary intracranial tumors. Part 8: Serological responses to active immunization of patients with anaplastic gliomas.

D. Bigner, G. Gillespie, C. Wikstrand, 1983, Journal of neurosurgery.

Phenotypic Analysis of Four Human Medulloblastoma Cell Lines and Transplantable Xenografts

J. Trojanowski, D. Bigner, S. Bigner, 1989, Journal of neuropathology and experimental neurology.

Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody.

D. Bigner, T. Matthews, H. Furthmayr, 1983, Cancer research.

Monoclonal anti-GD3 antibodies selectively inhibit the proliferation of human malignant glioma cells in vitro

P. Fredman, C. Wikstrand, K. Hedberg, 2000, Glycoconjugate Journal.

MRP3: a molecular target for human glioblastoma multiforme immunotherapy.

R. McLendon, G. Riggins, D. Bigner, 2010, BMC Cancer.

Chapter 16 Detection of glioma-associated gangliosides GM2, GD2, GD3, 3′-isoLM1 and 3′,6′-isoLD1 in central nervous system tumors in vitro and in vivo using epitope-defined monoclonal antibodies

D. Bigner, P. Fredman, C. Wikstrand, 1994 .

Surface antigenic characteristics of human glial brain tumor cells.

D. Bigner, C. Wikstrand, M. Mahaley, 1977, Cancer research.

Hyperimmunization of non-human primates with BCG-CW and cultured human glioma-derived cells Production of reactive antisera and absence of EAE induction

D. Bigner, C. Wikstrand, 1981, Journal of Neuroimmunology.

Biomarker Discovery in Central Nervous System Neoplasms: Past, Present and Future

R. McLendon, D. Bigner, C. Wikstrand, 2012 .

Specific chromosomal abnormalities characterize four established cell lines derived from malignant human gliomas

D. Bigner, J. Biegel, R. Gebhardt, 2004, Acta Neuropathologica.

Antigenic heterogeneity of human anaplastic gliomas and glioma-derived cell lines defined by monoclonal antibodies.

D. Bigner, R. Mccomb, C. Wikstrand, 1985, Journal of neuropathology and experimental neurology.

Circulating glycoconjugates in CSF of meningioma patients

D. Bigner, P. Davidsson, L. Svennerholm, 1990, Acta neurologica Scandinavica.

Gangliosides in the human glioma cell line U-118 MG grown in culture or as xenografts in nude rats.

D. Bigner, S. Bigner, J. Månsson, 1990, Biochimica et biophysica acta.

Expression of O6-methylguanine-DNA methyltransferase in six human medulloblastoma cell lines.

S. Batra, L. Ostrowski, S. Bigner, 1992, Cancer research.

Expression of 06-Methylguanine-DNA Methyltransferase in Six Human Medulloblastoma Cell Lines 1

D. Bigner, S. Batra, L. Ostrowski, 2006 .

Differentiation characteristics of newly established medulloblastoma cell lines (D384 Med, D425 Med, and D458 Med) and their transplantable xenografts.

J. Trojanowski, D. Bigner, S. Bigner, 1991, Laboratory investigation; a journal of technical methods and pathology.

Construction of an Immunotoxin, D2C7-(scdsFv)-PE38KDEL, Targeting EGFRwt and EGFRvIII for Brain Tumor Therapy

R. McLendon, I. Pastan, S. Keir, 2013, Clinical Cancer Research.

Progress Report of a Phase I Study of the Intracerebral Microinfusion of a Recombinant Chimeric Protein Composed of Transforming Growth Factor (TGF)-α and a Mutated form of the Pseudomonas Exotoxin Termed PE-38 (TP-38) for the Treatment of Malignant Brain Tumors

M. Berger, R. McLendon, A. Friedman, 2003, Journal of Neuro-Oncology.

Tumor antigens in astrocytic gliomas

R. McLendon, D. Bigner, S. Kurpad, 1995, Glia.

Molecular Targeting and Treatment of Composite EGFR and EGFRvIII-Positive Gliomas Using Boronated Monoclonal Antibodies

M. Moeschberger, K. Tordoff, M. Ciesielski, 2008, Clinical Cancer Research.

Relationship of in Vitro Morphologic and Growth Characteristics of Established Human Glioma‐derived Cell Lines to Their Tumorigenicity in Athymic Nude Mice

D. Bigner, S. Bigner, D. Bullard, 1981, Journal of neuropathology and experimental neurology.

The male antigen. II. Regulation of the primary and secondary responses to H-Y by H-2 associated genes.

C. Wikstrand, D. Bailey, G. Haughton, 1974, Cellular immunology.

Production and characterization of two human glioma xenograft-localizing monoclonal antibodies.

R. McLendon, D. Bigner, L. Svennerholm, 1986, Cancer research.

Monoclonal Antibody Therapy of Human Gliomas: Current Status and Future Approaches

D. Bigner, J. Sampson, I. Cokgor, 2004, Cancer and Metastasis Reviews.

Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas.

R. McLendon, P. Humphrey, D. Bigner, 1995, Cancer research.

EGFRvIII: an oncogene deletion mutant cell surface receptor target expressed by multiple tumour types

D. Bigner, J. Sampson, C. Wikstrand, 2000 .

Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting

Jennifer L Hunt, D. Bigner, J. Grandis, 2006, Clinical Cancer Research.

Monoclonal antibodies reactive with epitopes restricted to glial fibrillary acidic proteins of several species.

D. Bigner, Y. L. Lee, L. Eng, 1983, Neurochemical pathology.

Phase II trial of gefitinib in recurrent glioblastoma.

Allan H Friedman, R. McLendon, A. Friedman, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identifying potential tumor markers and antigens by database mining and rapid expression screening.

R. Strausberg, M. Marra, G. Riggins, 2000, Genome research.

Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.

R. Coleman, R. McLendon, A. Friedman, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

How heterogeneous are gliomas?

D. Bigner, S. Bigner, D. Bullard, 1981, Cancer treatment reports.

Molecular Targeting and Treatment of EGFRvIII-Positive Gliomas Using Boronated Monoclonal Antibody L8A4

M. Moeschberger, A. Ferketich, M. Ciesielski, 2006, Clinical Cancer Research.

Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts.

M. Willingham, D. Bigner, S. Kurpad, 1995, Cancer research.

Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors.

R. McLendon, D. Bigner, E. Lipp, 2012, Nuclear medicine and biology.

Constitutive activation of truncated EGF receptors in glioblastoma

D. Bigner, C. Wikstrand, 2008 .

Relevance for Neurobiology and Neurooncology of Antigens of Malignant Gliomas As Defined by Monoclonal Antibodies a

D. Bigner, C. Wikstrand, F. D. Vrionis, 1988, Annals of the New York Academy of Sciences.

Disialoganglioside GD2 in human neuroectodermal tumor cell lines and gliomas

G. Fuller, S. Bigner, L. Svennerholm, 1991, Acta Neuropathologica.

A preliminary study utilizing viable HLA mismatched cultured glioma cells as adjuvant therapy for patients with malignant gliomas.

D. Bigner, D. Thomas, J. Bodmer, 1985, British Journal of Cancer.

The use of a panel of monoclonal antibodies in the evaluation of cytologic specimens from the central nervous system.

D. Bigner, S. Bigner, J. Schlom, 1987, Acta cytologica.

Radiolabeled Antibodies for Therapy of Brain Tumors

D. Bigner, M. Zalutsky, C. Wikstrand, 2001 .

Investigation of a synthetic peptide as immunogen for a variant epidermal growth factor receptor associated with gliomas

P. Humphrey, D. Bigner, M. Shibuya, 1993, Journal of Neuroimmunology.

Tenascin and microvessel stromal changes in patients with non-Hodgkin's lymphoma are isolated to the sites of disease and vary in correlation to disease activity

D. Bigner, D. Niedzwiecki, M. Wadleigh, 2005, Leukemia & lymphoma.

Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system

D. Bigner, J. Sampson, C. Wikstrand, 2002, Cancer Immunology, Immunotherapy.

Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate.

D. Bigner, M. Zalutsky, C. Reist, 1997, Cancer research.

Long Term Response in a Patient with Neoplastic Meningitis Secondary to Melanoma Treated with 131 I-Radiolabeled Antichondroitin Proteoglycan

A. Friedman, D. Bigner, J. Provenzale, 2001 .

GD3 expression by cultured human tumor cells of neuroectodermal origin

J. Månsson, P. Fredman, C. Wikstrand, 2004, Acta Neuropathologica.

MOLECULAR AND IMMUNOHISTOLOGIC (IHC) STUDIES ON OLIGODENDROGLIAL (O) TUMORS

R. McLendon, D. Bigner, S. Bigner, 1998 .

Detection of glioma-associated gangliosides GM2, GD2, GD3, 3'-isoLM1 3',6'-isoLD1 in central nervous system tumors in vitro and in vivo using epitope-defined monoclonal antibodies.

D. Bigner, L. Svennerholm, P. Fredman, 1994, Progress in brain research.

Specific Imaging of Human Brain Tumor Xenografts Utilizing Radiolabelled Monoclonal Antibodies (MAbs)

R. Coleman, P. Humphrey, D. Bigner, 1986, Nuklearmedizin.

10 ANTIGENIC HETEROGENEITY OF HUMAN MALIGNANT GLIOMAS (MGs) DEMONSTRATED BY REACTIVITY WITH 10 MONOCLONAL ANTIBODIES (MCAs)

D. Bigner, S. Bigner, R. Mccomb, 1983 .

A new ganglioside of the lactotetraose series, GalNAc-3'-isoLM1, detected in human meconium.

D. Bigner, J. Månsson, L. Svennerholm, 1989, The Journal of biological chemistry.

Altered expression of ganglioside phenotypes of human gliomas in vivo and in vitro

D. Bigner, L. Svennerholm, P. Fredman, 1994, Molecular and chemical neuropathology.